Fulcrum Therapeutics stock rises on Slate Medicines merger deal

Fulcrum Therapeutics Inc's shares climbed 3.5% on Monday after the company announced a definitive agreement to merge with Slate Medicines Inc in an all-stock transaction. The newly formed company will be known as Slate Medicines and will concentrate on developing Slate's migraine therapeutics portfolio, including SLTE-1009, a clinical-stage subcutaneous anti-PACAP/VIP monoclonal antibody for migraine prevention.

Alongside the merger, Slate secured an oversubscribed private placement of $245 million from healthcare investors, led by Frazier Life Sciences. This financing also includes participation from various investment firms.

Following the merger, pre-merger Fulcrum stockholders will hold 5.0% of the combined entity, while pre-merger Slate stockholders, including financing participants, will collectively own 95.0%. Fulcrum is anticipated to contribute approximately $20.3 million in net cash to the merged company, and stockholders will receive a cash dividend of roughly $270.0 million immediately prior to closing.

The combined company's cash reserve at closing is projected to sustain operations until 2029 and facilitate the advancement of SLTE-1009 through Phase 1 healthy volunteer studies and Phase 2 dose-ranging trials in migraine patients.

SLTE-1009 is designed to target both PACAP and VIP, two neuropeptides implicated in migraine pathophysiology. The program has received clearance to commence Phase 1 clinical trials in Australia, with expected initial pharmacokinetic and safety data in mid-2027. The transaction received unanimous approval from both companies' boards and is expected to finalize in the fourth quarter of 2026, contingent upon stockholder approval and completion of customary closing conditions.

The merged company will be listed on Nasdaq under the ticker symbol SLTE and will be led by Gregory Oakes as Chief Executive Officer.